Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002962 (
angina
)
21,142
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In the period from 1968 to 1977, in the Departments of Cardiology of the S. Camillo Hospital, a study has been made about 200 cases of Congestive Cardiomyopathy (
MPC
) and 100 about hypertrophic obstructive (MP0). Congestive cardiomyopathies constitute 1.5% of hospitalizations with a constant trend in the long run. In comparing these two forms, Authors have noticed some differences in the symptomatology of clinical and instrumental signs: 1) in case of MPO prevail
angina
, syncope, ejection systolic murmur, left ventricular overload in the ECG; 2) in case of
MPC
they find more frequently heart failure, embolism, diastolic gallop, cardiomegaly, A/V and intraventricular conduction disturbs. The AA. conclude, in accordance with Goodwin's classification, that there is not an uniformity of these two kinds of cardiomyopathies.
...
PMID:[Epidemiological and clinical observations on 300 cases of primary myocardiopathy]. 45 5
The cardiovascular profile of a novel calcium antagonist,
MPC
-1304 and its active metabolites were investigated in experimental animals in vitro and in vivo, and were compared with those of other calcium antagonists or nitroglycerin (NTG). The ratio of negative chronotropic/negative inotropic effect of
MPC
-1304 was 23 times higher than that of nifedipine in paced left and spontaneously beating right atria of guinea pigs.
MPC
-1304 and nifedipine did not change atrial-His (AH) conduction time or His-ventricular (HV) conduction time at hypotensive doses in open-chest dogs, whereas diltiazem prolonged AH time.
MPC
-1304 increased coronary blood flow, and strongly decreased myocardial oxygen consumption (MVO2) by decreasing blood pressure (BP) and heart rate (HR) in open-chest dogs. Left ventricular pressure (LVP) was not changed. Contractile force (dp/dt) was slightly increased by its action on afterload.
MPC
-1304 and nifedipine did not dilate the large coronary artery, but NTG did.
MPC
-1304 increased blood flow of the peripheral arteries, especially vertebral and CBF in anesthetized dogs. Cerebral blood flow (CBF) also increased.
MPC
-1304 decreased serum cholesterol levels and the plaque area of the aorta in cholesterol-fed rabbits. Because of this cardiovascular profile,
MPC
-1304 should be useful in treatment of hypertension as well as
angina pectoris
.
...
PMID:Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: comparison with other calcium antagonists. 769 90
Early prediction of coronary artery disease complications is vital for the prevention and effective treatment of patients with coronary cardiac disease. It has been reported that inflammatory markers play a key role in the progression of cardiovascular diseases. Platelet count and platelet morphological parameters were analyzed on a fully-automated hematological analyzer ADVIA 2120 (Siemens). Serum myeloperoxidase (MPO) level was determined with an enzyme immunoassay (BioCheck). The measuring range of this assay is between 0 and 40 ng/ml. We demonstrate that serum MPO concentration and platelet activation increase systematically with the advancement of coronary artery disease. Moreover, MPO level is significantly higher in patients with unstable coronary artery disease and myocardial infarction compared with healthy subjects and patients with stable
angina
. The diagnostic sensitivity of these parameters was higher than of TnI (cardiac troponin I), CK-MB (creatine kinase-heart type), CRP (C-reactive protein), and fibrinogen and DD (D-dimers). MPO, L-PLT (large platelet), MPV (mean platelet volume), and
MPC
(mean platelet component concentration) may serve as attractive diagnostic and prognostic markers in the assessment of the risk for unstable atheroma in the course of coronary artery disease.
...
PMID:Serum myeloperoxidase levels and platelet activation parameters as diagnostic and prognostic markers in the course of coronary disease. 2111 86